Glucagon-like peptide-1 receptor agonists, such as semaglutide, are currently recommended for cardiovascular (CV) prevention only in patients with diabetes and high CV risk.1 They have also shown a >15% mean weight reduction benefit in patients without diabetes; however, it was previously unknown if they reduce CV risks in this population.2 The Semaglutide Effects on Cardiovascular […]
Representative results from participants showing atherosclerosis progression (left) and regression (disappearance of plaques, right) in arteries of the neck (carotids) and groin (femorals). Each image pair shows the results of the initial study at baseline and the follow-up study of the same artery six years later. The images show representative vascular ultrasound images on the […]
Thomas Schwann Corewell Health in Grand Rapids named Dr. Thomas A. Schwann as the new chief of cardiovascular surgery for Corewell Health in Southeast Michigan (formerly known as Beaumont Health). “We are proud and honored to give Dr. Schwann a warm welcome to our celebrated and nationally ranked cardiac surgery program,” says Dr. Penny Wilton, […]
“I think it’s probably been the single most important breakthrough in the cardiovascular space in the last ten years,” said Dr. Peter Soukas, the director of peripheral vascular interventional laboratory at The Miriam Hospital. It has been at the forefront of this innovative research, and now FDA approved treatment, for calcium blockages in coronary and […]
The U.S. Food and Drug Administration (FDA) has approved Medtronic’s Symplicity Spyral renal denervation (RDN) system for hypertension. This is the second RDN system to ever gain FDA approval for the treatment of hypertension. Recor Medical’s Paradise Ultrasound RDN system received the greenlight in early November. Medtronic’s Symplicity Spyral RDN system treats hypertension through the […]
Annual American Heart Association Scientific Sessions held in Philadelphia in November The American Heart Association Scientific Sessions 2023 brought together more than 15,000 research scientists, physicians, and cardiology professionals from throughout the world to present and discuss the latest scientific advancements, research, and evidence-based clinical practice updates in cardiovascular science. Matthew Solomon, MD, PhD, poster […]
Eli Lilly and Co. shared insights into an inhibitor targeting ANGPTL3, named solbinsiran. Solbinsiran, a N-acetylgalactosamine (GalNAc) conjugated Dicer-substrate small interfering RNA (DsiRNA), is designed to target ANGPTL3 expression in the liver.
Investigators from the Barbra Streisand Women’s Heart Center in the Smidt Heart Institute at Cedars-Sinai have found that among a cohort of women with obstructive coronary artery disease treated at academic medical centers, racial and ethnic disparities did not impact their long-term outcomes. The findings were recently published in the Canadian Journal of Cardiology. The […]
A new data analysis is showing that Americans are walking less often than they were before the COVID-19 pandemic, increasing their likelihood of experiencing serious health consequences. According to a new report from StreetLight Data, a data analytics company, the average amount of daily walking trips taken fell by 36% across the country in 2022 […]
Over the 12-week study, half of the participants drink a beverage each day containing freeze-dried wild blueberry powder, while the other half consume a placebo “We’re looking not just at nutrition, but how it impacts other factors — memory, cardiovascular health and other things that are very important — especially during the aging process for […]